<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Staar Surgical Company — News on 6ix</title>
    <link>https://6ix.com/company/staar-surgical-company</link>
    <description>Latest news and press releases for Staar Surgical Company on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/staar-surgical-company" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c42378dffbe2df11a0f9.webp</url>
      <title>Staar Surgical Company</title>
      <link>https://6ix.com/company/staar-surgical-company</link>
    </image>
    <item>
      <title>STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-announces-preliminary-net-sales-for-first-quarter-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-announces-preliminary-net-sales-for-first-quarter-2026</guid>
      <pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
      <description>LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer®</description>
    </item>
    <item>
      <title>STAAR Surgical Issues Shareholder Letter</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-issues-shareholder-letter</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-issues-shareholder-letter</guid>
      <pubDate>Tue, 03 Mar 2026 21:02:00 GMT</pubDate>
      <description>LAKE FOREST, Calif., March 03, 2026--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on Tuesday, March 3 after the market close. STAAR’s results release can be found here: https://investors.staar.com/news-and-events/press-releases.</description>
    </item>
    <item>
      <title>STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-reports-fourth-quarter-and-fiscal-year-2025-results</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-reports-fourth-quarter-and-fiscal-year-2025-results</guid>
      <pubDate>Tue, 03 Mar 2026 21:01:00 GMT</pubDate>
      <description>LAKE FOREST, Calif., March 03, 2026--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR’s Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/news-and-events/press-releases.</description>
    </item>
    <item>
      <title>STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-surpasses-4-million-icls-sold-globally-reflecting-ongoing-shift-away-from-laser-based-vision-correction</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-surpasses-4-million-icls-sold-globally-reflecting-ongoing-shift-away-from-laser-based-vision-correction</guid>
      <pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
      <description>LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer®</description>
    </item>
    <item>
      <title>STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-to-host-fourth-quarter-and-fiscal-year-2025-earnings-conference-call-and-webcast-on-march-3-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-to-host-fourth-quarter-and-fiscal-year-2025-earnings-conference-call-and-webcast-on-march-3-2026</guid>
      <pubDate>Mon, 23 Feb 2026 21:01:00 GMT</pubDate>
      <description>LAKE FOREST, Calif., February 23, 2026--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress.</description>
    </item>
    <item>
      <title>FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction</title>
      <link>https://6ix.com/company/staar-surgical-company/news/fda-expands-u-age-indication-210100263</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/fda-expands-u-age-indication-210100263</guid>
      <pubDate>Tue, 17 Feb 2026 21:01:00 GMT</pubDate>
      <description>LAKE FOREST, Calif., February 17, 2026--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian® Implantable Collamer Lenses, extending use to patients 21 to 60 years old. The approval came shortly after publication of three-year FDA clinical trial safety data, reinforcing</description>
    </item>
    <item>
      <title>STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-appoints-warren-foust-and-deborah-andrews-interim-co-ceos-2026-02-02</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-appoints-warren-foust-and-deborah-andrews-interim-co-ceos-2026-02-02</guid>
      <pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
      <description>Search Committee Has Initiated a Global Search to Select Next CEO LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (“STAAR” or the “Company”)</description>
    </item>
    <item>
      <title>STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-broadwood-partners-enter-133000330</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-broadwood-partners-enter-133000330</guid>
      <pubDate>Thu, 15 Jan 2026 13:30:00 GMT</pubDate>
      <description>LAKE FOREST, Calif., January 15, 2026--STAAR Surgical Company (&quot;STAAR&quot; or the &quot;Company&quot;) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. and its affiliates (&quot;Broadwood&quot;), which together own 31% of STAAR’s outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5% of ST</description>
    </item>
    <item>
      <title>STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-announces-preliminary-results-special-meeting-stockholders-2026-01-06</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-announces-preliminary-results-special-meeting-stockholders-2026-01-06</guid>
      <pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
      <description>STAAR Intends to Terminate Alcon Merger Agreement LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader</description>
    </item>
    <item>
      <title>Alcon Terminates Agreement to Acquire STAAR Surgical</title>
      <link>https://6ix.com/company/staar-surgical-company/news/alcon-terminates-agreement-to-acquire-staar-surgical</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/alcon-terminates-agreement-to-acquire-staar-surgical</guid>
      <pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR GENEVA--(BUSINESS WIRE)-- Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to</description>
    </item>
    <item>
      <title>Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders</title>
      <link>https://6ix.com/company/staar-surgical-company/news/alcon-exercises-right-to-require-staar-surgical-to-adjourn-its-special-meeting-of-stockholders-1</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/alcon-exercises-right-to-require-staar-surgical-to-adjourn-its-special-meeting-of-stockholders-1</guid>
      <pubDate>Fri, 19 Dec 2025 16:45:00 GMT</pubDate>
      <description>LAKE FOREST, Calif., December 19, 2025--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to require STAAR to adjourn its Special Meeting of Stockholders in connection with the Alcon merger agreement (the &quot;Special Meeting&quot;). As a result, the Special Meeting, which was scheduled for December 19, 2025 at 8:30 a.m. Pacific Time, has been adjourned to Janu</description>
    </item>
    <item>
      <title>Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical&apos;s Proposed Sale to Alcon Inc.</title>
      <link>https://6ix.com/company/staar-surgical-company/news/defender-capital-reiterates-intention-to-vote-against-staar-surgicals-proposed-sale-to-alcon-inc</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/defender-capital-reiterates-intention-to-vote-against-staar-surgicals-proposed-sale-to-alcon-inc</guid>
      <pubDate>Wed, 17 Dec 2025 21:53:00 GMT</pubDate>
      <description>Defender Capital (&quot;Defender&quot; or &quot;we&quot;), a long-term shareholder of STAAR Surgical Company (&quot;STAAR&quot; or the &quot;Company&quot;) (NASDAQ: STAA) owning approximately 1.5% of the Company&apos;s outstanding common stock, today issued the following statement reiterating its intention to vote AGAINST the Company&apos;s proposed sale to Alcon Inc. (&quot;Alcon&quot;) (NYSE: ALC) and expressing its disappointment in the Company&apos;s Board of Directors&apos; (the &quot;Board&quot;) continued pursuit of the deal:</description>
    </item>
    <item>
      <title>Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction</title>
      <link>https://6ix.com/company/staar-surgical-company/news/independent-industry-analysts-recognize-value-provided-staar-stockholders-amended</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/independent-industry-analysts-recognize-value-provided-staar-stockholders-amended</guid>
      <pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
      <description>Increased Alcon Merger Price of $30.75 per Share is an Attractive Outcome for STAAR Stockholders LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical</description>
    </item>
    <item>
      <title>Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger</title>
      <link>https://6ix.com/company/staar-surgical-company/news/leading-independent-proxy-advisory-firm-iss-recommends-staar-stockholders-vote-alcon</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/leading-independent-proxy-advisory-firm-iss-recommends-staar-stockholders-vote-alcon</guid>
      <pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
      <description>STAAR Urges Stockholders to Vote “FOR” Alcon Merger on the WHITE Proxy Card TODAY LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ:</description>
    </item>
    <item>
      <title>STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-sets-record-straight-regarding-its-robust-go-shop-process-2025-12-11</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-sets-record-straight-regarding-its-robust-go-shop-process-2025-12-11</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>Activist Investors Have Twisted Facts Regarding STAAR’s Engagement with a Potentially Interested Party During Go-Shop Process The Potentially Interested</description>
    </item>
    <item>
      <title>Alcon Announces Amended Merger Agreement with STAAR Surgical</title>
      <link>https://6ix.com/company/staar-surgical-company/news/alcon-announces-amended-merger-agreement-with-staar-surgical-1</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/alcon-announces-amended-merger-agreement-with-staar-surgical-1</guid>
      <pubDate>Tue, 09 Dec 2025 13:30:00 GMT</pubDate>
      <description>GENEVA, December 09, 2025--Alcon Announces Amended Merger Agreement with STAAR Surgical</description>
    </item>
    <item>
      <title>STAAR Surgical Announces Expiration of Go-Shop Period</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-announces-expiration-go-shop-period-2025-12-08</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-announces-expiration-go-shop-period-2025-12-08</guid>
      <pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
      <description>No Competing Acquisition Proposals Received Results of Go-Shop Process Validate the Effectiveness of the STAAR Board’s Process Now is the Right Time to Sell</description>
    </item>
    <item>
      <title>STAAR Surgical Announces Amendments to Alcon Merger Agreement</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-announces-amendments-alcon-merger-agreement-2025-11-07</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-announces-amendments-alcon-merger-agreement-2025-11-07</guid>
      <pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
      <description>30-Day Go-Shop Period to Actively Solicit Other Third-Party Proposals No Termination Fee Payable to Alcon if STAAR Terminates Merger Agreement to Accept a</description>
    </item>
    <item>
      <title>STAAR Surgical Reports Third Quarter 2025 Results</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-reports-third-quarter-2025-results-2025-11-05</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-reports-third-quarter-2025-results-2025-11-05</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer®</description>
    </item>
    <item>
      <title>STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon</title>
      <link>https://6ix.com/company/staar-surgical-company/news/staar-surgical-sets-new-record-date-and-postpones-staar-special-meeting-stockholders</link>
      <guid isPermaLink="true">https://6ix.com/company/staar-surgical-company/news/staar-surgical-sets-new-record-date-and-postpones-staar-special-meeting-stockholders</guid>
      <pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
      <description>STAAR Special Meeting of Stockholders Postponed to December 3, 2025 LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the</description>
    </item>
  </channel>
</rss>